Yvette Leung serves as the Head of Commercial Strategy & Business Development at Dyno Therapeutics, where she leverages her extensive biopharma and startup experience to drive innovative solutions in the rapidly evolving landscape of gene therapy. As a key member of the executive leadership team...
Yvette Leung serves as the Head of Commercial Strategy & Business Development at Dyno Therapeutics, where she leverages her extensive biopharma and startup experience to drive innovative solutions in the rapidly evolving landscape of gene therapy. As a key member of the executive leadership team at this a16z-backed company, Yvette has been instrumental in shaping the corporate development strategy, focusing on pipeline strategy and product launches that align with the company's mission to revolutionize gene delivery technologies.
Under her leadership, Dyno Therapeutics successfully built a robust Corporate Development team, encompassing Business Development, Strategy, Alliance Management, and External Communications. One of her notable achievements includes closing a groundbreaking gene delivery research collaboration with Astellas, valued at $1.6 billion, which underscores her expertise in identifying and executing high-value partnering opportunities. Yvette's strategic oversight of alliance management for five research collaborations with leading biopharmaceutical companies has further solidified Dyno's position in the industry, fostering relationships that drive organizational growth and innovation.
Known for her ability to cultivate high-performing teams, Yvette excels in cross-functional influence, ensuring that mission-critical workstreams are delivered efficiently and effectively. Her skills in product launch, corporate strategy, and project management are complemented by a deep understanding of hematology and genetics, positioning her as a thought leader in the biotech space. With a commitment to impact-focused initiatives, Yvette continues to navigate the complexities of the biopharma landscape, driving Dyno Therapeutics toward its vision of transforming gene therapy into a mainstream treatment modality.
